Ibandronate in benign bone disease
Winzenberg, TM and Jones, G (2008) Ibandronate in benign bone disease. Reviews on Recent Clinical Trials, 3 (2). pp. 139-149. ISSN 1574-8871
|PDF - Full text restricted - Requires a PDF viewer|
Official URL: http://www.benthamdirect.org/pages/content.php?RRCT
Ibandronate is a potent bisphosphonate which has been most thoroughly assessed in benign bone disease for use in the management of postmenopausal osteoporosis. Its use in corticosteroid-induced osteoporosis, Paget’s disease and uncommon benign bone conditions such as localised transient osteoporosis (or bone marrow oedema syndrome) and sternocostoclavicular hyperostosis has also been explored.
Recent randomised controlled trial evidence suggests that intermittent high dosage oral ibandronate may be as efficacious as a daily low dose regime for the treatment of post-menopausal osteoporosis, with only a mild increase in adverse events. Movement towards an extended gap between doses has implications for patient compliance and adherence and thus potential benefits for fracture prevention.
This review aims to provide an overview of the evidence from randomised controlled trials in humans for the use of ibandronate in benign bone diseases. This includes a discussion of the development program and dosage regimens for the prevention and treatment of post-menopausal osteoporosis, as well as the use of ibandronate in corticosteroid induced osteoporosis, Paget’s disease localised transient osteoporosis and sternoclavicular hyperostosis. Adverse effects and long-term safety data will also be reviewed.
|Additional Information:||© 2008 Bentham Science Publishers Ltd.|
|Keywords:||bone mineral density, Postmenopausal Osteoporosis, Osteoarthritis, type 1 collagen, Corticosteroid-Induced Osteoporosis, Pagets Disease|
|Deposited By:||Ms Emma Stubbs|
|Deposited On:||24 Nov 2008 11:22|
|Last Modified:||16 Mar 2009 10:30|
|ePrint Statistics:||View statistics for this ePrint|
Repository Staff Only: item control page